Thomas Fagan is Executive Vice President, Neurodegenerative Portfolio at Cognito Therapeutics, where he leads the strategic development and commercialization readiness of the company’s Alzheimer’s programs, including the Spectris AD™ therapeutic platform. With more than 25 years of experience across the pharmaceutical, medical device, and diagnostics industries, Mr. Fagan has built and led organizations responsible for bringing innovative technologies from clinical development to real-world adoption. Prior to joining Cognito, he served as Vice President, U.S. Alzheimer’s Disease Commercial at Eisai Inc., where he led the U.S. commercial strategy for the company’s Alzheimer’s portfolio and led the launch and market expansion of LEQEMBI® (lecanemab). Earlier in his career at Eli Lilly and Company, he held several leadership roles in Alzheimer’s disease programs, including Global Commercial Leader and Global Brand Development Leader, where he helped lead commercialization efforts for Amyvid® (florbetapir), the first FDA-approved PET imaging agent for detecting amyloid plaques associated with Alzheimer’s disease. Mr. Fagan began his career at Goldman Sachs and has also held leadership roles at Baxter International and Momentum Life Sciences. He earned his MBA from Stanford University and holds a Bachelor of Arts in Economics from DePauw University.
